T1	Participants 65 107	patients receiving intravenous antibiotics
T2	Participants 374 465	This study was specific for a patient group receiving prolonged courses of i.v. antibiotics
T3	Participants 625 694	Patients with cystic fibrosis receiving intermittent i.v. antibiotics
T4	Participants 1611 1653	patients requiring longer term i.v. access
